Holen Sie sich die Stockscreener-App
12.67
0.55%
-0.07
Handel nachbörslich:
12.58
-0.09
-0.71%
Schlusskurs vom Vortag:
$12.74
Offen:
$12.74
24-Stunden-Volumen:
2.36M
Relative Volume:
0.58
Marktkapitalisierung:
$1.68B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-766.97M
KGV:
-1.654
EPS:
-7.66
Netto-Cashflow:
$-646.43M
1W Leistung:
-0.08%
1M Leistung:
+13.63%
6M Leistung:
-6.15%
1J Leistung:
-68.27%
1-Tages-Spanne:
$12.26
$12.87
1-Wochen-Bereich:
$12.26
$14.01
52-Wochen-Spanne:
$7.48
$44.28
Biohaven Ltd Stock (BHVN) Company Profile
Firmenname
Biohaven Ltd
Sektor
Branche
Telefon
203-404-0410
Adresse
215 CHURCH STREET, NEW HAVEN, CT
Vergleichen Sie BHVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
12.67 | 1.69B | 0 | -766.97M | -646.43M | -7.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-21 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-12-03 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | Herabstufung | UBS | Buy → Neutral |
| 2025-11-06 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-09-17 | Eingeleitet | Citigroup | Buy |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-05-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-09-16 | Eingeleitet | Jefferies | Buy |
| 2024-09-04 | Eingeleitet | Bernstein | Outperform |
| 2024-07-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2023-12-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-01-24 | Eingeleitet | SVB Securities | Outperform |
| 2023-01-04 | Eingeleitet | JP Morgan | Overweight |
| 2022-12-02 | Eingeleitet | BTIG Research | Buy |
| 2022-10-26 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-05-11 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-08-10 | Herabstufung | UBS | Buy → Neutral |
| 2021-08-03 | Bestätigt | Canaccord Genuity | Buy |
| 2021-03-11 | Eingeleitet | UBS | Buy |
| 2020-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-17 | Eingeleitet | Cowen | Outperform |
| 2020-02-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2019-11-22 | Eingeleitet | Wedbush | Outperform |
| 2019-06-25 | Bestätigt | Canaccord Genuity | Buy |
| 2019-05-06 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | Bestätigt | Needham | Buy |
| 2018-07-03 | Bestätigt | Needham | Buy |
| 2018-07-02 | Bestätigt | Needham | Buy |
| 2018-04-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2018-02-22 | Bestätigt | Canaccord Genuity | Buy |
| 2017-12-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-10-03 | Bestätigt | Needham | Buy |
Alle ansehen
Biohaven Ltd Aktie (BHVN) Neueste Nachrichten
Aug Action: Is First Merchants Corporation attractive for institutional investorsEarnings Risk Summary & Real-Time Volume Triggers - baoquankhu1.vn
Jim Cramer on Biohaven: “The Stock Seems Very Low to Me” - MSN
Assessing Biohaven (BHVN) Valuation After A Sharp Momentum Rebound - Yahoo Finance
Biohaven (NYSE:BHVN) Shares Gap UpWhat's Next? - MarketBeat
This Albemarle Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
RBC Capital Upgrades Biohaven (BHVN) - Nasdaq
BHVN Upgraded by RBC Capital: New Price Target of $22 | BHVN Sto - GuruFocus
RBC Upgrades Biohaven to Outperform From Sector Perform, Boosts Price Target to $22 From $9, Keeps Speculative Risk - marketscreener.com
Biohaven stock rating upgraded by RBC Capital on promising CNS data - Investing.com South Africa
(BHVN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Biohaven (BHVN) Is Up 15.6% After Showcasing MoDE and TRAP Degrader Data in Autoimmune Diseases - Sahm
JPM26: After a Tough 2025, Biohaven Is Gearing Up To Challenge Goliath—Lilly - BioSpace
Assessing Biohaven (BHVN) Valuation After Positive MoDE And TRAP Degrader Clinical Updates - Sahm
Pomerantz To Lead Biohaven Investors' FDA Approval Suit - Law360
Biohaven (NYSE:BHVN) Stock Price Up 8%Still a Buy? - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Shares Surge 3.42% to $12.10 Amid Positive Clinical Data - Intellectia AI
Biohaven (BHVN) Stock Is Trending Overnight — Here's What You Should Know - Benzinga
BHVN SEC FilingsBiohaven 10-K, 10-Q, 8-K Forms - Stock Titan
Can Biohaven Ltd. deliver alphaMarket Weekly Review & Low Risk High Reward Ideas - bollywoodhelpline.com
Biohaven Ltd. (BHVN) Investor Outlook: Navigating Opportunities with a 68% Upside Potential - DirectorsTalk Interviews
Biohaven (NYSE:BHVN) Shares Down 6.3%Here's Why - MarketBeat
Biohaven (BHVN) Is Up 19.2% After Early Success With Selective Antibody Degraders In Kidney, Thyroid Diseases - simplywall.st
Biohaven stock maintains Outperform rating at Baird on promising IgAN data - Investing.com
Biohaven stock maintains Outperform rating at Baird on promising IgAN data By Investing.com - Investing.com South Africa
Biohaven highlights degrader platforms in new investor presentation - TipRanks
Biohaven Ltd Announces Investor Presentation on January 12, 2026 - TradingView
Biohaven reports early patient data from protein degrader programs - StreetInsider
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 - PR Newswire
Aug Update: Is Biohaven Ltd stock oversold or undervaluedJuly 2025 Volume & AI Driven Stock Price Forecasts - Bộ Nội Vụ
Biohaven Ltd. (BHVN) upgraded to buy: Here's what you should know - MSN
(BHVN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Jobs Data: Why Biohaven Ltd stock attracts global investorsWeekly Stock Recap & AI Based Buy/Sell Signal Reports - moha.gov.vn
Volatility Watch: Why Biohaven Ltd stock attracts global investorsEarnings Growth Summary & Real-Time Volume Triggers - moha.gov.vn
Will Biohaven Ltd. stock continue dividend increasesQuarterly Profit Review & Verified Chart Pattern Signals - Улправда
Is Biohaven Ltd. stock overvalued by current metricsMarket Risk Report & AI Forecast for Swing Trade Picks - Улправда
Will Biohaven Ltd. stock recover faster than peersTrade Volume Report & Daily Risk Controlled Trade Plans - ulpravda.ru
Aug Final Week: Is Biohaven Ltd. stock oversold or undervaluedQuarterly Portfolio Report & Long-Term Growth Stock Strategies - Улправда
Is Biohaven Ltd. stock oversold or undervalued2025 Buyback Activity & Low Drawdown Investment Ideas - Улправда
Biohaven (NYSE:BHVN) Shares Up 11.9%Here's Why - MarketBeat
Biohaven expects to raise $125M in stock sale - Hartford Business Journal
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Co - GuruFocus
Biohaven Announces $125 Million Targeted Equity Financing - TipRanks
Biohaven Ltd. Announces $125 Million Share Sale - TradingView — Track All Markets
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a Potential 96% Upside in the Biotech Sector - DirectorsTalk Interviews
Why Biohaven Ltd. Common Shares stock is a strong analyst pick2026 world cup usa national team round of 32 star players transition play knockout prediction preview - ulpravda.ru
Morgan Stanley Lowers Price Target for Biohaven (BHVN) to $21 | - GuruFocus
Morgan Stanley Issues Pessimistic Forecast for Biohaven (NYSE:BHVN) Stock Price - MarketBeat
Stock market today: Dow Jones, S&P 500 futures slip after Christmas Day—Nvidia, Sobr Safe, Biohaven in focus - MSN
Biohaven Ltd. (NYSE:BHVN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Biohaven (NYSE:BHVN) Trading Down 8%Here's What Happened - MarketBeat
Finanzdaten der Biohaven Ltd-Aktie (BHVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):